Loading
An international study of 2,658 whole cancer genomes found that almost every tumour contains distinct branches carrying their own mutations.
The Pan-Cancer Analysis of Whole Genomes heterogeneity group characterised intra-tumour heterogeneity across whole-genome sequences of 2,658 cancer samples spanning 38 cancer types. Nearly all informative samples (95.1 per cent) contained evidence of distinct subclonal expansions, with frequent branching relationships between subclones, and the authors observed positive selection of subclonal driver mutations across most cancer types.
Nearly every tumour has subclones, so a residual disease result built only from shared trunk mutations cannot say which branch is left.
Shares Cell, Naming which clone or phenotype is left after treatment, Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Naming which clone or phenotype is left after treatment, Whole-exome & whole-genome sequencing, Breast cancer (all types).
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Naming which clone or phenotype is left after treatment, Breast cancer (all types).
Shares Tumour heterogeneity and clonal evolution, Whole-exome & whole-genome sequencing.
Shares Naming which clone or phenotype is left after treatment, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/